Sakellariou Grigorios T, Chatzigiannis Ioannis
Department of Rheumatology, St. Paul's Hospital, 161 Ethnikis Andistaseos Str, 55134, Thessaloniki, Greece.
Clin Rheumatol. 2007 Jun;26(6):950-2. doi: 10.1007/s10067-006-0392-1. Epub 2006 Jul 25.
Anti-TNFalpha therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNFalpha agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNFalpha therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.
对于患有慢性丙型肝炎的患者，抗TNFα疗法治疗风湿性疾病似乎是安全的。然而，在慢性HBV感染患者中，未启动预防性抗病毒治疗（拉米夫定100毫克/天）就给予抗TNFα药物会导致肝病加重。在本报告中，我们描述了在两名未进行预防性抗病毒治疗的无症状HBsAg携带者中进行强直性脊柱炎长期抗TNFα治疗的经验。
